Over 100 lifespan with medical tech

 

Companies that seek to postpone human mortality will be one of the most lucrative investment opportunities over the following ten years, with experts from Bank of America projecting that this sector will be valued at least $600 billion by 2025.

Companies like Illumina and Alphabet, according to the experts, are poised to "deliver unprecedented advances to the quality and length of human lifespans."

The Bank of America team highlights six stocks that have exposure to the trend as well as five major sub-themes.

A prominent Wall Street investment bank predicts that by 2025, the market for companies that seek to postpone human mortality would be valued at least $600 billion, making it one of the best areas to invest. 

Genome sequencers like Illumina, high-tech corporations like Alphabet, and biotech firms like Novartis, according to analysts Felix Tran and Haim Israel of Bank of America Merrill Lynch, are poised to "deliver extraordinary advances to the quality and duration of human lifespans."


According to BofA, advances in genetic science, big data, and "ammortality," which includes wearable technology and items in the so-called wellness sector, might soon extend a healthy person's life well into 100 years. 

By 2020, medical knowledge would quadruple every 73 days as opposed to every 3.5 (years) in 2010, and the cost of genome sequencing has decreased 99.999 percent since 2003, according to a study by Israel and Tran.
Because of this, a "techmanity" (technology meets mankind) revolution has begun, significantly extending life expectancy through a new frontier in precision medicine.


Extending human existence to new frontiers, a longtime staple of science fiction literature, may become an increasingly appealing method to profit from the public markets.
The Bank of America team identified five main sub-themes — genomics, big data/AI health, future food, "ammortality," and "moonshot medicine" — as well as a number of equities that provide exposure to the trend. The market size is already $110 billion. 

 

Genomics

By 2025, Bank of America projects that the field of genomics, or the study of the human genome, would generate $41 billion in revenue and give rise to the "next generation of gene editing technologies delivering potentially transformative advancements in preventive and disease therapies."


Companies with exposure to the market include the $46 billion genome sequencer Illumina, the $27 billion manufacturer of lab instruments Agilent, and the $89 billion producer of life science equipment Danaher.


According to Tran and Israel, Illumina in particular "plays a major role in aiding illness research, drug development, and the establishment of molecular testing." 

AI/Big Data Health

In the coming years, researchers should be better able to evaluate pathology, or the study of the causes and effects of diseases, thanks to the development of artificial intelligence and an expanding amount of health-care data.
According to the BofA analysts, technological advancements could lower healthcare expenses and make precision treatment possible.


The parent company of Google, Alphabet, Amazon (including its joint venture with Berkshire Hathaway and J.P. Morgan Chase), and Apple are among the major players in this market, which is anticipated to reach $36 billion by 2025. 

future meals

Dow DuPont and WW International are two future food firms that are projected to "guarantee better eating and sustainable humanity on the earth."
According to BofA, these businesses should make use of agricultural gene editing as well as healthier eating and lifestyle choices. 

 

‘Ammortality’

By 2025, it is anticipated that the "ammortality" subject would be worth $504 billion. This theme "will help to increase health spans & [lifespans] to the betterment of human vitality, enabling the world population to live freer of sickness rather than forever," according to the report.


Health-care technology companies like Intuitive Surgical and Zimmer, which collaborated with Apple Watch to launch a clinical study for 10,000 knee and hip replacement patients, are examples of companies that BofA refers to as "ammortality" investments. 

The "Moonshot drug"

The aforementioned Illumina and genomics firms, as well as therapeutic manufacturers like Sangamo, Vertex Pharma, and Neurocrine, are examples of "Moonshot medicine" companies, or those that provide ground-breaking solutions for healthcare.


These businesses are striving to develop therapies or solutions for some of humanity's most difficult ailments, including cystic fibrosis, Parkinson's disease, and Alzheimer's disease.